These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

568 related items for PubMed ID: 17089011

  • 1. DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate fatty acid synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and TOP2A genes.
    Menendez JA, Vellon L, Lupu R.
    Int J Mol Med; 2006 Dec; 18(6):1081-7. PubMed ID: 17089011
    [Abstract] [Full Text] [Related]

  • 2. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
    Menendez JA, Mehmi I, Atlas E, Colomer R, Lupu R.
    Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
    [Abstract] [Full Text] [Related]

  • 3. Overexpression and hyperactivity of breast cancer-associated fatty acid synthase (oncogenic antigen-519) is insensitive to normal arachidonic fatty acid-induced suppression in lipogenic tissues but it is selectively inhibited by tumoricidal alpha-linolenic and gamma-linolenic fatty acids: a novel mechanism by which dietary fat can alter mammary tumorigenesis.
    Menendez JA, Ropero S, Mehmi I, Atlas E, Colomer R, Lupu R.
    Int J Oncol; 2004 Jun; 24(6):1369-83. PubMed ID: 15138577
    [Abstract] [Full Text] [Related]

  • 4. Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells.
    Menendez JA, Vellon L, Lupu R.
    Med Hypotheses; 2005 Jun; 64(5):997-1001. PubMed ID: 15780499
    [Abstract] [Full Text] [Related]

  • 5. Does endogenous fatty acid metabolism allow cancer cells to sense hypoxia and mediate hypoxic vasodilatation? Characterization of a novel molecular connection between fatty acid synthase (FAS) and hypoxia-inducible factor-1alpha (HIF-1alpha)-related expression of vascular endothelial growth factor (VEGF) in cancer cells overexpressing her-2/neu oncogene.
    Menendez JA, Vellon L, Oza BP, Lupu R.
    J Cell Biochem; 2005 Apr 01; 94(5):857-63. PubMed ID: 15669079
    [Abstract] [Full Text] [Related]

  • 6. Pharmacological inhibition of fatty acid synthase (FAS): a novel therapeutic approach for breast cancer chemoprevention through its ability to suppress Her-2/neu (erbB-2) oncogene-induced malignant transformation.
    Menendez JA, Mehmi I, Verma VA, Teng PK, Lupu R.
    Mol Carcinog; 2004 Nov 01; 41(3):164-78. PubMed ID: 15390078
    [Abstract] [Full Text] [Related]

  • 7. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
    Menendez JA, Vellon L, Lupu R.
    Ann Oncol; 2005 Aug 01; 16(8):1253-67. PubMed ID: 15870086
    [Abstract] [Full Text] [Related]

  • 8. Induction of sensitivity to doxorubicin and etoposide by transfection of MCF-7 breast cancer cells with heregulin beta-2.
    Harris LN, Yang L, Tang C, Yang D, Lupu R.
    Clin Cancer Res; 1998 Apr 01; 4(4):1005-12. PubMed ID: 9563896
    [Abstract] [Full Text] [Related]

  • 9. In support of fatty acid synthase (FAS) as a metabolic oncogene: extracellular acidosis acts in an epigenetic fashion activating FAS gene expression in cancer cells.
    Menendez JA, Decker JP, Lupu R.
    J Cell Biochem; 2005 Jan 01; 94(1):1-4. PubMed ID: 15523670
    [Abstract] [Full Text] [Related]

  • 10. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
    Scandinavian Breast Group Trial 9401Laboratory of Cancer Biology, Institute of Medical Technology, and Department of Oncology, Tampere University and Tampere University Hospital, Tampere, Finland., Tanner M, Isola J, Wiklund T, Erikstein B, Kellokumpu-Lehtinen P, Malmström P, Wilking N, Nilsson J, Bergh J.
    J Clin Oncol; 2006 Jun 01; 24(16):2428-36. PubMed ID: 16682728
    [Abstract] [Full Text] [Related]

  • 11. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
    Vazquez-Martin A, Colomer R, Brunet J, Menendez JA.
    Int J Oncol; 2007 Oct 01; 31(4):769-76. PubMed ID: 17786307
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of tumor-associated fatty acid synthase hyperactivity induces synergistic chemosensitization of HER -2/ neu -overexpressing human breast cancer cells to docetaxel (taxotere).
    Menendez JA, Lupu R, Colomer R.
    Breast Cancer Res Treat; 2004 Mar 01; 84(2):183-95. PubMed ID: 14999148
    [Abstract] [Full Text] [Related]

  • 13. Simultaneous amplification of HER-2 (ERBB2) and topoisomerase IIalpha (TOP2A) genes--molecular basis for combination chemotherapy in cancer.
    Järvinen TA, Liu ET.
    Curr Cancer Drug Targets; 2006 Nov 01; 6(7):579-602. PubMed ID: 17100565
    [Abstract] [Full Text] [Related]

  • 14. RNA interference-mediated silencing of the p53 tumor-suppressor protein drastically increases apoptosis after inhibition of endogenous fatty acid metabolism in breast cancer cells.
    Menendez JA, Lupu R.
    Int J Mol Med; 2005 Jan 01; 15(1):33-40. PubMed ID: 15583825
    [Abstract] [Full Text] [Related]

  • 15. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
    Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, Coombs D, Baly D, Kabbinavar F, Slamon D.
    Oncogene; 1999 Apr 01; 18(13):2241-51. PubMed ID: 10327070
    [Abstract] [Full Text] [Related]

  • 16. A genomic explanation connecting "Mediterranean diet", olive oil and cancer: oleic acid, the main monounsaturated fatty acid of olive oil, induces formation of inhibitory "PEA3 transcription factor-PEA3 DNA binding site" complexes at the Her-2/neu (erbB-2) oncogene promoter in breast, ovarian and stomach cancer cells.
    Menendez JA, Papadimitropoulou A, Vellon L, Lupu R.
    Eur J Cancer; 2006 Oct 01; 42(15):2425-32. PubMed ID: 16406575
    [Abstract] [Full Text] [Related]

  • 17. Her-2/neu and topoisomerase IIα in advanced breast cancer: a comprehensive FISH analysis of 245 cases.
    Engelstaedter V, Schiffers J, Kahlert S, Mainka P, Engel J, Kirchner T, Diebold J, Mayr D.
    Diagn Mol Pathol; 2012 Jun 01; 21(2):77-83. PubMed ID: 22555090
    [Abstract] [Full Text] [Related]

  • 18. Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines.
    Gong SJ, Jin CJ, Rha SY, Chung HC.
    Cancer Lett; 2004 Oct 28; 214(2):215-24. PubMed ID: 15363548
    [Abstract] [Full Text] [Related]

  • 19. Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer.
    Järvinen TA, Tanner M, Bärlund M, Borg A, Isola J.
    Genes Chromosomes Cancer; 1999 Oct 28; 26(2):142-50. PubMed ID: 10469452
    [Abstract] [Full Text] [Related]

  • 20. Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity.
    Menendez JA, Vellon L, Colomer R, Lupu R.
    Int J Cancer; 2005 May 20; 115(1):19-35. PubMed ID: 15657900
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.